JP2012092127A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012092127A5 JP2012092127A5 JP2011275858A JP2011275858A JP2012092127A5 JP 2012092127 A5 JP2012092127 A5 JP 2012092127A5 JP 2011275858 A JP2011275858 A JP 2011275858A JP 2011275858 A JP2011275858 A JP 2011275858A JP 2012092127 A5 JP2012092127 A5 JP 2012092127A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- active substance
- pharmaceutical formulation
- combination
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 230000001078 anti-cholinergic effect Effects 0.000 claims 5
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 5
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 4
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims 3
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims 3
- 239000000150 Sympathomimetic Substances 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 2
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 2
- 150000007925 phenylethylamine derivatives Chemical class 0.000 claims 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 2
- 229940127230 sympathomimetic drug Drugs 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 claims 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical group CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims 1
- BDNMABJZSXTKAQ-VCPDFFEISA-N 3-(diethylamino)propyl (1r,4s)-3-phenylbicyclo[2.2.1]heptane-3-carboxylate Chemical compound CCN(CC)CCCOC(=O)C1([C@H]2CC[C@H](C2)C1)C1=CC=CC=C1 BDNMABJZSXTKAQ-VCPDFFEISA-N 0.000 claims 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 1
- 229930003347 Atropine Natural products 0.000 claims 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 1
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
- 108010062431 Monoamine oxidase Proteins 0.000 claims 1
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 claims 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims 1
- 229940124639 Selective inhibitor Drugs 0.000 claims 1
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 claims 1
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 1
- 229960002274 atenolol Drugs 0.000 claims 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 1
- 229960000396 atropine Drugs 0.000 claims 1
- 229940092732 belladonna alkaloid Drugs 0.000 claims 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 1
- 229960000911 benserazide Drugs 0.000 claims 1
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims 1
- 229960001081 benzatropine Drugs 0.000 claims 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 claims 1
- GERIGMSHTUAXSI-UHFFFAOYSA-N bis(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-phenyl-2,3-dihydro-1h-naphthalene-1,4-dicarboxylate Chemical compound CN1C(C2)CCC1CC2OC(=O)C(C1=CC=CC=C11)CCC1(C(=O)OC1CC2CCC(N2C)C1)C1=CC=CC=C1 GERIGMSHTUAXSI-UHFFFAOYSA-N 0.000 claims 1
- 229960001793 bornaprine Drugs 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960004596 cabergoline Drugs 0.000 claims 1
- 229960004205 carbidopa Drugs 0.000 claims 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
- 229940052760 dopamine agonists Drugs 0.000 claims 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims 1
- 229960003337 entacapone Drugs 0.000 claims 1
- 108010009400 levodopa receptor Proteins 0.000 claims 1
- 229960003587 lisuride Drugs 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- MJFJKKXQDNNUJF-UHFFFAOYSA-N metixene Chemical compound C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 MJFJKKXQDNNUJF-UHFFFAOYSA-N 0.000 claims 1
- 229960005103 metixene Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 claims 1
- 229960003941 orphenadrine Drugs 0.000 claims 1
- 229960004851 pergolide Drugs 0.000 claims 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims 1
- 229960002508 pindolol Drugs 0.000 claims 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 1
- 229960003089 pramipexole Drugs 0.000 claims 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims 1
- 229960005253 procyclidine Drugs 0.000 claims 1
- 229960003712 propranolol Drugs 0.000 claims 1
- -1 pyrivezil Chemical compound 0.000 claims 1
- 229960001879 ropinirole Drugs 0.000 claims 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 1
- 229960003179 rotigotine Drugs 0.000 claims 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 1
- 229960002646 scopolamine Drugs 0.000 claims 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical group C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims 1
- 229960003946 selegiline Drugs 0.000 claims 1
- 229960004558 terguride Drugs 0.000 claims 1
- 229960004605 timolol Drugs 0.000 claims 1
- 229960001032 trihexyphenidyl Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10338174.0 | 2003-08-20 | ||
| DE10338174A DE10338174A1 (de) | 2003-08-20 | 2003-08-20 | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523588A Division JP2007502795A (ja) | 2003-08-20 | 2004-08-14 | パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012092127A JP2012092127A (ja) | 2012-05-17 |
| JP2012092127A5 true JP2012092127A5 (enExample) | 2013-03-07 |
| JP5827114B2 JP5827114B2 (ja) | 2015-12-02 |
Family
ID=34201721
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523588A Withdrawn JP2007502795A (ja) | 2003-08-20 | 2004-08-14 | パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 |
| JP2011275858A Expired - Lifetime JP5827114B2 (ja) | 2003-08-20 | 2011-12-16 | パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523588A Withdrawn JP2007502795A (ja) | 2003-08-20 | 2004-08-14 | パーキンソン病を処置するための活性成分の組み合わせを含有する経皮適用医薬製剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8980308B2 (enExample) |
| EP (1) | EP1656122B2 (enExample) |
| JP (2) | JP2007502795A (enExample) |
| KR (1) | KR20060065692A (enExample) |
| CN (1) | CN1832732A (enExample) |
| AT (1) | ATE446744T1 (enExample) |
| AU (1) | AU2004266063B2 (enExample) |
| BR (1) | BRPI0412054A (enExample) |
| CA (1) | CA2535063C (enExample) |
| DE (2) | DE10338174A1 (enExample) |
| DK (1) | DK1656122T4 (enExample) |
| ES (1) | ES2335771T5 (enExample) |
| IL (1) | IL173712A (enExample) |
| MX (1) | MXPA06001815A (enExample) |
| NZ (1) | NZ545593A (enExample) |
| PL (1) | PL1656122T5 (enExample) |
| PT (1) | PT1656122E (enExample) |
| RU (1) | RU2397757C2 (enExample) |
| SI (1) | SI1656122T2 (enExample) |
| WO (1) | WO2005018619A1 (enExample) |
| ZA (1) | ZA200509779B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10338174A1 (de) * | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| US20070191815A1 (en) | 2004-09-13 | 2007-08-16 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| WO2007013830A1 (en) | 2005-07-26 | 2007-02-01 | Portela & Ca. S.A. | Nitrocatechol derivatives as comt inhibitors |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| DK2481410T3 (en) | 2007-01-31 | 2016-10-24 | Bial - Portela & Ca S A | Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen |
| RU2326660C1 (ru) * | 2007-03-14 | 2008-06-20 | Закрытое акционерное общество "Биологические исследования и системы" | Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты) |
| EP1977746B8 (en) * | 2007-04-02 | 2014-09-24 | Parkinson's Institute | Methods and compositions for reduction of side effects of therapeutic treatments |
| EP2150239A1 (en) * | 2007-04-24 | 2010-02-10 | Boehringer Ingelheim International GmbH | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| BRPI0913913A2 (pt) * | 2008-07-29 | 2015-10-13 | Bial Portela & Ca Sa | regime de dosagem para nitrocatecóis |
| CN102448444B (zh) | 2009-04-01 | 2016-05-25 | 巴尔-波特拉及康邦亚股份有限公司 | 包括硝基儿茶酚衍生物的药物制剂及其制备方法 |
| KR101292768B1 (ko) * | 2010-04-23 | 2013-08-05 | 아이큐어 주식회사 | 경피 흡수 제제 |
| JP5820469B2 (ja) | 2010-04-30 | 2015-11-24 | テイコク ファーマ ユーエスエー インコーポレーテッド | プロピニルアミノインダンの経皮組成物 |
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| EP2705842A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| EP2688561B1 (en) | 2011-03-24 | 2018-08-22 | Teikoku Pharma USA, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| US20130017259A1 (en) | 2011-07-06 | 2013-01-17 | The Parkinson's Institute | Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients |
| EP2776020B1 (en) | 2011-11-09 | 2019-09-11 | Teikoku Seiyaku Co., Ltd. | Methods for the treatment of skin neoplasms |
| US9126988B2 (en) | 2011-12-13 | 2015-09-08 | Bial—Portela & Ca, S.A. | Intermediate for preparing a catechol-O-methyltransferase inhibitor |
| US20130197023A1 (en) * | 2012-01-27 | 2013-08-01 | California Institute Of Technology | Neuroprotection by pharmacological chaperoning of nicotinic acetylcholine receptors |
| JP6050896B2 (ja) | 2012-11-02 | 2016-12-21 | テイコク ファーマ ユーエスエー インコーポレーテッド | プロピニルアミノインダン経皮組成物 |
| US10105487B2 (en) | 2013-01-24 | 2018-10-23 | Chrono Therapeutics Inc. | Optimized bio-synchronous bioactive agent delivery system |
| US10111879B2 (en) | 2013-06-27 | 2018-10-30 | Cedars-Sinai Medical Center | Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions |
| CN103622997A (zh) * | 2013-11-22 | 2014-03-12 | 内蒙古医科大学 | 包含谷氨酸受体阻断剂盐酸美金刚或其药学可接受的盐与β受体阻断剂的药物组合物 |
| EP2946775A1 (de) | 2014-05-20 | 2015-11-25 | LTS LOHMANN Therapie-Systeme AG | Lavendelöl enthaltendes transdermales therapeutisches System |
| WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| CN104510725B (zh) * | 2015-01-22 | 2021-04-27 | 中国药科大学 | 一种普拉克索周效透皮贴剂及其制备方法 |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| AU2016228779A1 (en) | 2015-03-12 | 2017-09-07 | Chrono Therapeutics Inc. | Craving input and support system |
| CN114668747A (zh) * | 2016-10-07 | 2022-06-28 | 全崴生技股份有限公司 | 普拉克索经皮贴片系统与用法 |
| WO2018129304A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| AU2019279884B2 (en) | 2018-05-29 | 2025-01-30 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| JP2022507660A (ja) | 2018-11-16 | 2022-01-18 | モーニングサイド ベンチャー インベストメンツ リミテッド | 温度によって調節される経皮薬剤送達システム |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| US20240299501A1 (en) * | 2023-03-06 | 2024-09-12 | Xygenyx Inc. | Composition and methods of treatment using transdermal hormone supplementation |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
| JPH0611698B2 (ja) | 1984-12-19 | 1994-02-16 | 大正製薬株式会社 | 貼付剤 |
| US4666441A (en) * | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
| DE3710966A1 (de) | 1986-04-16 | 1987-12-03 | Degussa | Synergistische kombination von amantadin und selegilin |
| EP0241809B1 (de) * | 1986-04-16 | 1990-08-08 | ASTA Pharma Aktiengesellschaft | Synergistische Kombination von Amantadin und Selegilin |
| US4877618A (en) * | 1988-03-18 | 1989-10-31 | Reed Jr Fred D | Transdermal drug delivery device |
| GB8807504D0 (en) * | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
| US4963568A (en) * | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| BR9306816A (pt) * | 1992-07-28 | 1998-12-08 | Procter & Gamble | Composição farmaceutica para uso tópico contendo um polímero catiônico reticulado e um eter alcoxilado |
| US5462746A (en) * | 1992-11-02 | 1995-10-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation |
| DE4332094C2 (de) * | 1993-09-22 | 1995-09-07 | Lohmann Therapie Syst Lts | Lösemittelfrei herstellbares Wirkstoffpflaster und Verfahren zu seiner Herstellung |
| US5744476A (en) * | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| US5601839A (en) * | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
| GB9511366D0 (en) | 1995-06-06 | 1995-08-02 | Smithkline Beecham Plc | Novel formulations |
| CA2223588C (en) * | 1995-06-07 | 2004-01-06 | Noven Pharmaceuticals, Inc. | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| US5807570A (en) * | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
| US6929801B2 (en) * | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| DE19626621A1 (de) * | 1996-07-02 | 1998-01-08 | Hexal Ag | Pflaster zur transdermalen Anwendung von Pergolid |
| US5877173A (en) * | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
| JPH11209271A (ja) * | 1998-01-23 | 1999-08-03 | Nitto Denko Corp | 経皮吸収製剤 |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| PL196413B1 (pl) | 1999-02-05 | 2007-12-31 | Cipla Ltd | Kompozycja lecznicza, dozownik zawierający kompozycję leczniczą, sposób przygotowania dozownika i zastosowanie kompozycji |
| US6465004B1 (en) | 1999-06-05 | 2002-10-15 | Noven Pharmaceuticals, Inc. | Solubility enhancement of drugs in transdermal drug delivery systems and methods of use |
| DE19938823A1 (de) | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| FR2798065B1 (fr) | 1999-09-02 | 2003-09-05 | Assist Publ Hopitaux De Paris | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson |
| JP2002097137A (ja) * | 2000-07-19 | 2002-04-02 | Junichi Sudo | パーキンソン病の予防および／または治療剤 |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| US20030119884A1 (en) * | 2000-11-01 | 2003-06-26 | Epstein Mel H. | Methods and compositions for regulating memory consolidation |
| DE10064453A1 (de) | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| CA2381630A1 (en) | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Method for preventing dyskinesias |
| ES2204780T3 (es) | 2001-05-08 | 2004-05-01 | Schwarz Pharma Ag | Sistema terapeutico transdermico para la enfermedad de parkinson que induce altos niveles de rotigotina en plasma. |
| PT1256340E (pt) * | 2001-05-08 | 2003-12-31 | Sanol Arznei Schwarz Gmbh | Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson |
| US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
-
2003
- 2003-08-20 DE DE10338174A patent/DE10338174A1/de not_active Withdrawn
-
2004
- 2004-08-14 PT PT04764129T patent/PT1656122E/pt unknown
- 2004-08-14 US US10/568,941 patent/US8980308B2/en active Active
- 2004-08-14 EP EP04764129A patent/EP1656122B2/de not_active Expired - Lifetime
- 2004-08-14 DE DE502004010303T patent/DE502004010303D1/de not_active Expired - Lifetime
- 2004-08-14 ES ES04764129T patent/ES2335771T5/es not_active Expired - Lifetime
- 2004-08-14 RU RU2005141214/15A patent/RU2397757C2/ru not_active IP Right Cessation
- 2004-08-14 KR KR1020067003176A patent/KR20060065692A/ko not_active Ceased
- 2004-08-14 MX MXPA06001815A patent/MXPA06001815A/es active IP Right Grant
- 2004-08-14 NZ NZ545593A patent/NZ545593A/en not_active IP Right Cessation
- 2004-08-14 DK DK04764129.5T patent/DK1656122T4/da active
- 2004-08-14 CN CNA2004800225495A patent/CN1832732A/zh active Pending
- 2004-08-14 WO PCT/EP2004/009136 patent/WO2005018619A1/de not_active Ceased
- 2004-08-14 AU AU2004266063A patent/AU2004266063B2/en not_active Ceased
- 2004-08-14 AT AT04764129T patent/ATE446744T1/de active
- 2004-08-14 BR BRPI0412054-0A patent/BRPI0412054A/pt not_active IP Right Cessation
- 2004-08-14 JP JP2006523588A patent/JP2007502795A/ja not_active Withdrawn
- 2004-08-14 CA CA2535063A patent/CA2535063C/en not_active Expired - Fee Related
- 2004-08-14 SI SI200431317T patent/SI1656122T2/sl unknown
- 2004-08-14 PL PL04764129T patent/PL1656122T5/pl unknown
-
2005
- 2005-12-02 ZA ZA200509779A patent/ZA200509779B/en unknown
-
2006
- 2006-02-13 IL IL173712A patent/IL173712A/en not_active IP Right Cessation
-
2011
- 2011-12-16 JP JP2011275858A patent/JP5827114B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005141214A (ru) | Чрескожный лекарственный препарат для лечения болезни паркинсона, содержащий сочетания действующих веществ | |
| Hallett et al. | Rationale for and use of NMDA receptor antagonists in Parkinson's disease | |
| ES2393211T3 (es) | Uso de 2-aminotetralinas sustituidas para la fabricación de un medicamento para la prevención, alivio y/o tratamiento de diversos tipos de dolor | |
| Chen et al. | Transdermal rotigotine: A clinically innovative dopamine‐receptor agonist for the management of Parkinson's disease | |
| JP2013542246A5 (enExample) | ||
| JP5253707B2 (ja) | レストレスレッグス症候群を処置するための経外角皮的投与形 | |
| HRP20171469T1 (hr) | Novi terapijski pristupi u liječenju parkinsonove bolesti | |
| JP2013543482A5 (enExample) | ||
| JP2012520883A5 (enExample) | ||
| EP4512484A3 (en) | Excipients for nicotine-containing therapeutic compositions | |
| JP2011137020A5 (enExample) | ||
| JP2012512907A5 (enExample) | ||
| CL2012003171A1 (es) | Compuestos derivados de ciclohexilamina, con actividad dual agonista con el receptor m3 muscarinico y agonista con el receptor b2 adrenérgicos; composición farmacéutica que comprende un compuesto; combinación; farmaceutica; y su uso de un compuesto en la preparacion de medicamento de enfermedades respiratorias. | |
| CN109982699A (zh) | 一种mor激动剂与kor激动剂的药物组合物及其用途 | |
| JP2016539156A5 (enExample) | ||
| BR112013009004A2 (pt) | combinações de agonistas de receptor de serotonina para o tratamento de distúrbios de movimento | |
| JP2016504368A5 (enExample) | ||
| RU2011104146A (ru) | Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи | |
| JP2015514739A5 (enExample) | ||
| AU2013299885A1 (en) | Pramipexole transdermal delivery for severe headaches | |
| JP2015524470A5 (enExample) | ||
| JP2009500398A5 (enExample) | ||
| IL275091B1 (en) | Methods for treating gaucher disease | |
| Chen et al. | Community and long-term care management of Parkinson’s disease in the elderly: focus on monoamine oxidase type B inhibitors | |
| JP2017008044A (ja) | ドーパミンシグナル伝達の抑制剤 |